BCDA — BioCardia, Inc.
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 17
- Website: https://www.biocardia.com
Latest SEC filings for BCDA
- 8-K — 2026-08-24
- 8-K — 2026-08-21
- 8-K — 2026-08-12
- 10-Q — 2026-08-12
- 8-K — 2026-06-18
- 8-K — 2026-06-12
- 8-K — 2026-06-08
- 8-K — 2026-06-05
- 8-K — 2026-05-28
- 8-K — 2026-05-21
Latest BCDA news
- — BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire Inc.)
- — BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter (globenewswire.com)
Educational tool only — not investment advice.